Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 215.31 USD 3.36%
Market Cap: 10.6B USD

Charles River Laboratories International Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Charles River Laboratories International Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Charles River Laboratories International Inc
NYSE:CRL
Free Cash Flow
$543.7m
CAGR 3-Years
25%
CAGR 5-Years
4%
CAGR 10-Years
9%
Thermo Fisher Scientific Inc
NYSE:TMO
Free Cash Flow
$6.1B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Free Cash Flow
$5B
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Free Cash Flow
$889.5m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
10%
Agilent Technologies Inc
NYSE:A
Free Cash Flow
$1.1B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
-1%
IQVIA Holdings Inc
NYSE:IQV
Free Cash Flow
$2.2B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
17%
No Stocks Found

Charles River Laboratories International Inc
Glance View

Nestled within the intricate maze of the global life sciences sector, Charles River Laboratories International Inc. stands as a pivotal player. With a legacy dating back to 1947, the company has carved out a niche in providing essential research models and preclinical services that underpin crucial drug development processes. Its journey began by breeding laboratory animals, an unassuming yet vital task that feeds the robust pipeline of scientific inquiry and pharmaceutical innovation. This foundational service, involving the provision of research models such as rats and mice, forms the bedrock upon which the company built its expansive portfolio. It primes the pumps of early-stage research for pharmaceutical and biotechnology firms, offering a reliable source of high-quality, disease-specific models that are indispensable for preclinical trials. Today, Charles River Laboratories has evolved into a comprehensive partner for the biomedical and pharmaceutical industries. It derives its revenue by encompassing a broad portfolio of offerings beyond animal models, venturing into the vast domain of comprehensive drug discovery and safety testing for new pharmaceuticals. This makes the company instrumental in speeding up the development pipeline—from concept to the cusp of clinical trials. By providing everything from lab services, safety assessments, and manufacturing support, Charles River facilitates the journey of a drug from an embryonic idea to a tangible, market-ready solution, all while ensuring compliance with strict regulatory standards. This integration across verticals not only enriches its value proposition but ensures a steady stream of revenue across various stages of the drug development lifecycle.

CRL Intrinsic Value
223.96 USD
Undervaluation 4%
Intrinsic Value
Price

See Also

What is Charles River Laboratories International Inc's Free Cash Flow?
Free Cash Flow
543.7m USD

Based on the financial report for Sep 27, 2025, Charles River Laboratories International Inc's Free Cash Flow amounts to 543.7m USD.

What is Charles River Laboratories International Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
9%

Over the last year, the Free Cash Flow growth was -3%. The average annual Free Cash Flow growth rates for Charles River Laboratories International Inc have been 25% over the past three years , 4% over the past five years , and 9% over the past ten years .

Back to Top